ATE306295T1 - Diclofenac zur behandlung von vasculopathien - Google Patents

Diclofenac zur behandlung von vasculopathien

Info

Publication number
ATE306295T1
ATE306295T1 AT97906922T AT97906922T ATE306295T1 AT E306295 T1 ATE306295 T1 AT E306295T1 AT 97906922 T AT97906922 T AT 97906922T AT 97906922 T AT97906922 T AT 97906922T AT E306295 T1 ATE306295 T1 AT E306295T1
Authority
AT
Austria
Prior art keywords
albumin
nonenzymatic glycation
apo
protect
compounds
Prior art date
Application number
AT97906922T
Other languages
English (en)
Inventor
Margo P Cohen
Rex Clements
Original Assignee
Exocell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exocell Inc filed Critical Exocell Inc
Application granted granted Critical
Publication of ATE306295T1 publication Critical patent/ATE306295T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Feed For Specific Animals (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Testing Of Short-Circuits, Discontinuities, Leakage, Or Incorrect Line Connections (AREA)
  • Polyesters Or Polycarbonates (AREA)
AT97906922T 1996-02-20 1997-02-19 Diclofenac zur behandlung von vasculopathien ATE306295T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60314796A 1996-02-20 1996-02-20
PCT/US1997/002622 WO1997029746A1 (en) 1996-02-20 1997-02-19 Inhibition of protein glycation and prevention of vasculopathy

Publications (1)

Publication Number Publication Date
ATE306295T1 true ATE306295T1 (de) 2005-10-15

Family

ID=24414273

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906922T ATE306295T1 (de) 1996-02-20 1997-02-19 Diclofenac zur behandlung von vasculopathien

Country Status (5)

Country Link
EP (1) EP0946170B8 (de)
JP (1) JP2002515031A (de)
AT (1) ATE306295T1 (de)
DE (1) DE69734356T2 (de)
WO (1) WO1997029746A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355680B1 (en) 1996-02-20 2002-03-12 Exocell, Inc. Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
KR101166290B1 (ko) 2009-08-24 2012-07-16 영남대학교 산학협력단 아포지단백질 α－ｉ의 당화 억제제 스크리닝 방법
CN104840768A (zh) * 2015-04-28 2015-08-19 王新花 一种治疗气阴两虚型肾小球源性血尿的中药制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060626A (en) * 1972-01-26 1977-11-29 Boehringer Mannheim G.M.B.H. Indole-carboxylic carbon compounds and pharmaceutical compositions containing them
US5245046A (en) * 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents

Also Published As

Publication number Publication date
DE69734356T2 (de) 2006-07-06
DE69734356D1 (de) 2006-02-23
EP0946170B8 (de) 2005-12-07
EP0946170A4 (de) 2002-03-20
EP0946170B1 (de) 2005-10-12
JP2002515031A (ja) 2002-05-21
WO1997029746A1 (en) 1997-08-21
EP0946170A1 (de) 1999-10-06

Similar Documents

Publication Publication Date Title
RU94031747A (ru) Соединения и способы лечения
BR0008176A (pt) Derivados anti-convulsivantes úteis no tratamento de cefaléias em cacho
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
EA200000868A1 (ru) Ингибиторы фосфолипаз
DK0865294T3 (da) Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
ATE174905T1 (de) Wasserlösliche organische salze von kreatin
DE69534120D1 (de) Topisch anzuwendende ketoconazol enthaltende emulsionen
ATE252830T1 (de) Neue psoralene zur inaktivierung von pathogenen
DK0658348T3 (da) Vandige opløsninger af inklusionskomplekser af benzothiophenforbindelser og cyclodextriner
EP1985285A3 (de) Zusammensetzungen und Verfahren zur Behandlung von Lymphomen
AU5915100A (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
ATE271865T1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE306295T1 (de) Diclofenac zur behandlung von vasculopathien
EA199800685A1 (ru) Разделение компонентов плазмы крови с помощью фильтрующих средств на основе целлюлозы
ATE157876T1 (de) Wirkstofffreie liposomen zur behandlung von atherosklerose
CA2407654A1 (en) Liposome containing hydrophobic iodine compound
DE69636907D1 (de) Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
ATE132154T1 (de) Bis (4-(2,6-dialkyl)phenol)silan derivate als antiatherosclerotische mittel und als antioxidantien
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
MacKenzie et al. Effects of superoxide dismutase mimetics on the activity of nitric oxide in rat aorta
EA200000851A1 (ru) Е - 2 - [4 - (4 - хлор - 1, 2 - дифенил - бут - 1 - енил) фенокси] этанол и фармацевтические композиции на его основе
CA2246657A1 (en) Inhibition of protein glycation and prevention of vasculopathy
DE50110552D1 (de) Verfahren zur behandlung von instabiler angina pectoris
ATE179882T1 (de) 2-phasen-haarbehandlungsmittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties